Gastrointestinal Cancer Articles

Pfizer Acquires Array BioPharma in $11.4 Billion Deal
Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.
Tumor Sidedness Opens Door for Personalized Therapy in Colorectal Cancer
Sujatha Nallapareddy, MD, discusses how personalized therapy has improved the outlook for patients with colorectal cancer and sheds light on some of the challenges that lie ahead.
SM-88 Shows Efficacy in Pancreatic, Prostate Cancers
Having a late-stage treatment for pancreatic cancer that avoids many of the adverse events associated with chemotherapy would be a boon for patients.
Christopher Lieu, MD, highlights updates on biomarker-directed therapy with colorectal cancer and ongoing research being done with immunotherapy.
Ramucirumab/TAS-102 Combo Aims to Overcome Toxicities in Gastric/GEJ Cancer
Rutika Mehta, MD, MPH, provides insight on the ongoing study combining TAS-102 with ramucirumab in the treatment of patients with advanced gastric/GEJ cancer.
Management of Newly Diagnosed mCRC Driven by Molecular Markers
Wells A. Messersmith, MD, discusses the evolving standards of care in colorectal cancer and the importance of molecular testing in guiding treatment decisions.
Immunotherapy Generates Excitement in Gastric/GEJ Cancers
S. Lindsey Davis, MD, highlights the latest immunotherapy developments and other advances in gastric and gastroesophageal junction cancers.
Laparoscopic Surgery Found to Be Noninferior to Open Surgery Method for CRC Liver Metastases
Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.
Maintenance Olaparib Improves PFS in BRCA+ Metastatic Pancreatic Cancer
Maintenance therapy with olaparib significantly improved progression-free survival compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.
Frontline Pembrolizumab Induces Comparable OS, Fewer AEs in Advanced GEJ Cancer
Frontline pembrolizumab demonstrated non-inferior overall survival compared with standard chemotherapy among patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
Publication Bottom Border
Border Publication